Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer

Phillip L. Ross, Iona Cheng, Xin Liu, Mine Cicek, Peter R. Carroll, Graham Casey, John S. Witte

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Carboxypeptidase 4 (CPA4) is a zinc-dependent metallocarboxypeptidase on chromosome 7q32 in a region linked to prostate cancer aggressiveness. CPA4 is involved in the histone hyperacetylation pathway and may modulate the function of peptides that affect the growth and regulation of prostate epithelial cells. We examined the association between genetic variation in CPA4 and intermediate-to-high risk prostate cancer. Methods: We studied 1012 men(506 cases and 506 controls) from Cleveland, Ohio. All cases had Gleason ≥ 7, clinical stage ≥ T2c, or PSA ≥ 10 ng/mL at diagnosis. Six CPA4 single-nucleotide polymorphisms were genotyped, and evaluated for their relation to prostate cancer. We also evaluated whether CPA4 variants influence risk of disease among men diagnosed at an earlier age (< 66 years). Results: The nonsynonymous coding SNP (rs2171492, Cys303Gly) in CPA4 was associated with an increased risk of aggressive prostate cancer among younger patients (< 66 years). Specifically, men carrying the TT genotype had an approximately two-fold increased risk for being diagnosed with intermediate-to-high risk disease (Odds Ratio = 1.83, p = 0.04). In the overall population (all ages) none of the CPA4 SNPs demonstrated a statistically significant association with prostate cancer. Conclusion: Coding variation in CPA4 may confer increased risk of intermediate-to-high risk prostate cancer among younger patients. Further work is needed to identify the functional aspects of this variation and understand its biological effects on prostate cancer. Such work may translate into more precise screening of higher risk individuals as well as guiding clinicians and patients toward earlier and more definitive treatment modalities in patients genetically identified as higher risk.

Original languageEnglish (US)
Article number69
JournalBMC Cancer
Volume9
DOIs
StatePublished - Feb 26 2009

Fingerprint

Carboxypeptidases
Prostatic Neoplasms
Genes
Single Nucleotide Polymorphism
Histones
Zinc
Prostate
Chromosomes
Epithelial Cells
Odds Ratio
Genotype
Peptides

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. / Ross, Phillip L.; Cheng, Iona; Liu, Xin; Cicek, Mine; Carroll, Peter R.; Casey, Graham; Witte, John S.

In: BMC Cancer, Vol. 9, 69, 26.02.2009.

Research output: Contribution to journalArticle

Ross, Phillip L. ; Cheng, Iona ; Liu, Xin ; Cicek, Mine ; Carroll, Peter R. ; Casey, Graham ; Witte, John S. / Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. In: BMC Cancer. 2009 ; Vol. 9.
@article{485964f3d4aa4e1c947ff63e9ff37b62,
title = "Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer",
abstract = "Background: Carboxypeptidase 4 (CPA4) is a zinc-dependent metallocarboxypeptidase on chromosome 7q32 in a region linked to prostate cancer aggressiveness. CPA4 is involved in the histone hyperacetylation pathway and may modulate the function of peptides that affect the growth and regulation of prostate epithelial cells. We examined the association between genetic variation in CPA4 and intermediate-to-high risk prostate cancer. Methods: We studied 1012 men(506 cases and 506 controls) from Cleveland, Ohio. All cases had Gleason ≥ 7, clinical stage ≥ T2c, or PSA ≥ 10 ng/mL at diagnosis. Six CPA4 single-nucleotide polymorphisms were genotyped, and evaluated for their relation to prostate cancer. We also evaluated whether CPA4 variants influence risk of disease among men diagnosed at an earlier age (< 66 years). Results: The nonsynonymous coding SNP (rs2171492, Cys303Gly) in CPA4 was associated with an increased risk of aggressive prostate cancer among younger patients (< 66 years). Specifically, men carrying the TT genotype had an approximately two-fold increased risk for being diagnosed with intermediate-to-high risk disease (Odds Ratio = 1.83, p = 0.04). In the overall population (all ages) none of the CPA4 SNPs demonstrated a statistically significant association with prostate cancer. Conclusion: Coding variation in CPA4 may confer increased risk of intermediate-to-high risk prostate cancer among younger patients. Further work is needed to identify the functional aspects of this variation and understand its biological effects on prostate cancer. Such work may translate into more precise screening of higher risk individuals as well as guiding clinicians and patients toward earlier and more definitive treatment modalities in patients genetically identified as higher risk.",
author = "Ross, {Phillip L.} and Iona Cheng and Xin Liu and Mine Cicek and Carroll, {Peter R.} and Graham Casey and Witte, {John S.}",
year = "2009",
month = "2",
day = "26",
doi = "10.1186/1471-2407-9-69",
language = "English (US)",
volume = "9",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer

AU - Ross, Phillip L.

AU - Cheng, Iona

AU - Liu, Xin

AU - Cicek, Mine

AU - Carroll, Peter R.

AU - Casey, Graham

AU - Witte, John S.

PY - 2009/2/26

Y1 - 2009/2/26

N2 - Background: Carboxypeptidase 4 (CPA4) is a zinc-dependent metallocarboxypeptidase on chromosome 7q32 in a region linked to prostate cancer aggressiveness. CPA4 is involved in the histone hyperacetylation pathway and may modulate the function of peptides that affect the growth and regulation of prostate epithelial cells. We examined the association between genetic variation in CPA4 and intermediate-to-high risk prostate cancer. Methods: We studied 1012 men(506 cases and 506 controls) from Cleveland, Ohio. All cases had Gleason ≥ 7, clinical stage ≥ T2c, or PSA ≥ 10 ng/mL at diagnosis. Six CPA4 single-nucleotide polymorphisms were genotyped, and evaluated for their relation to prostate cancer. We also evaluated whether CPA4 variants influence risk of disease among men diagnosed at an earlier age (< 66 years). Results: The nonsynonymous coding SNP (rs2171492, Cys303Gly) in CPA4 was associated with an increased risk of aggressive prostate cancer among younger patients (< 66 years). Specifically, men carrying the TT genotype had an approximately two-fold increased risk for being diagnosed with intermediate-to-high risk disease (Odds Ratio = 1.83, p = 0.04). In the overall population (all ages) none of the CPA4 SNPs demonstrated a statistically significant association with prostate cancer. Conclusion: Coding variation in CPA4 may confer increased risk of intermediate-to-high risk prostate cancer among younger patients. Further work is needed to identify the functional aspects of this variation and understand its biological effects on prostate cancer. Such work may translate into more precise screening of higher risk individuals as well as guiding clinicians and patients toward earlier and more definitive treatment modalities in patients genetically identified as higher risk.

AB - Background: Carboxypeptidase 4 (CPA4) is a zinc-dependent metallocarboxypeptidase on chromosome 7q32 in a region linked to prostate cancer aggressiveness. CPA4 is involved in the histone hyperacetylation pathway and may modulate the function of peptides that affect the growth and regulation of prostate epithelial cells. We examined the association between genetic variation in CPA4 and intermediate-to-high risk prostate cancer. Methods: We studied 1012 men(506 cases and 506 controls) from Cleveland, Ohio. All cases had Gleason ≥ 7, clinical stage ≥ T2c, or PSA ≥ 10 ng/mL at diagnosis. Six CPA4 single-nucleotide polymorphisms were genotyped, and evaluated for their relation to prostate cancer. We also evaluated whether CPA4 variants influence risk of disease among men diagnosed at an earlier age (< 66 years). Results: The nonsynonymous coding SNP (rs2171492, Cys303Gly) in CPA4 was associated with an increased risk of aggressive prostate cancer among younger patients (< 66 years). Specifically, men carrying the TT genotype had an approximately two-fold increased risk for being diagnosed with intermediate-to-high risk disease (Odds Ratio = 1.83, p = 0.04). In the overall population (all ages) none of the CPA4 SNPs demonstrated a statistically significant association with prostate cancer. Conclusion: Coding variation in CPA4 may confer increased risk of intermediate-to-high risk prostate cancer among younger patients. Further work is needed to identify the functional aspects of this variation and understand its biological effects on prostate cancer. Such work may translate into more precise screening of higher risk individuals as well as guiding clinicians and patients toward earlier and more definitive treatment modalities in patients genetically identified as higher risk.

UR - http://www.scopus.com/inward/record.url?scp=63049106920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049106920&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-9-69

DO - 10.1186/1471-2407-9-69

M3 - Article

C2 - 19245716

AN - SCOPUS:63049106920

VL - 9

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 69

ER -